For research use only. Not for therapeutic Use.
BAR502(CAT: I013636) is a dual agonist of farnesoid X receptor (FXR) and G-protein-coupled bile acid receptor 1 (GPBAR1, also known as TGR5), with IC₅₀ values of 2 μM and 0.4 μM, respectively. By activating FXR, BAR502 regulates bile acid homeostasis, lipid metabolism, and inflammation, while GPBAR1 activation modulates energy expenditure, glucose metabolism, and immune responses. This dual activity makes BAR502 a valuable tool in metabolic disease research, particularly for studying conditions such as non-alcoholic fatty liver disease (NAFLD), diabetes, and cholestasis. Its mechanism provides insights into the therapeutic potential of targeting bile acid receptors for metabolic and inflammatory disorders.
| Catalog Number | I013636 |
| CAS Number | 1612191-86-2 |
| Molecular Formula | C₂₅H₄₄O₃ |
| Purity | ≥95% |
| Target | Metabolic Enzyme/Protease |
| Solubility | DMSO: 10mM |
| IUPAC Name | (3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-17-[(2R)-4-hydroxybutan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol |
| InChI | InChI=1S/C25H44O3/c1-5-17-21-14-16(27)8-11-25(21,4)20-9-12-24(3)18(15(2)10-13-26)6-7-19(24)22(20)23(17)28/h15-23,26-28H,5-14H2,1-4H3/t15-,16-,17-,18-,19+,20+,21+,22+,23-,24-,25-/m1/s1 |
| InChIKey | HYCMOIGNYNCMRH-APIYUPOTSA-N |
| SMILES | CCC1C2CC(CCC2(C3CCC4(C(C3C1O)CCC4C(C)CCO)C)C)O |
